The new PMPRB Meds Entry Watch annual publication explores the market entry dynamics of new drugs launched in Canada and other international markets. This first edition of the report provides both a retrospective analysis of the new drugs launched over a six-year period from 2009 to 2014, and an early analysis of drugs launched in 2015.

Key Findings:

• New active substances (NASs) account for a sizable share of the Canadian and international pharmaceutical market.
• A comparable number of NASs are launched in Canada as in other foreign markets, and all top-selling NASs are available in Canada.
• The top-selling NASs account for most of the sales in Canada and the PMPRB7 and are dominated by the new direct-acting antiviral (DAA) treatments for hepatitis C.
• High-priced drugs dominate the NASs launched in 2015, many being biologic, orphan and/or oncology drugs.

The full report is available at the following link.